jetcityimage/iStock Editorial via Getty Images Eli Lilly ( NYSE: LLY ) said a Phase 3b study of its drug Ebglyss showed it was able to improve skin and itch in patients with moderate-to-severe atopic dermatitis who had previously been treated with dupilumab, also known as Dupixent. Lilly added.
Back to Health Page
